Contact us
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...
Press releases
The latest information on our progress towards reaching our goals
14 November 2025
Angiex Completes $31M Financings for Phase 1 Clinical Development of AGX101
Angiex Completes Financings Totaling $31M to Support the Phase 1 Clinical Development of AGX101 in Patients with Advanced Solid Tumors
07 August 2024
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
29 September 2022
07 September 2022
18 August 2021
